Jupiter Neurosciences, Inc. filings document a clinical-stage pharmaceutical issuer with common stock listed on the Nasdaq Capital Market and a business built around the JOTROL™ resveratrol platform and Nugevia™ products. Material-event reports cover standby equity purchase and registration-rights agreements, convertible promissory notes, amendments to installment provisions, and Nasdaq continued-listing notices.
Proxy materials disclose annual meeting matters, board governance and stockholder voting procedures. Rule 12b-25 notices document delayed periodic reports for annual and quarterly filings, while capital-structure disclosures address common stock, potential share issuances and related financing limitations.
JUPITER NEUROSCIENCES, INC. director Brady Allison W received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036.
The grant was made under the company’s 2025 Equity Incentive Plan. The options vest over three years starting September 2, 2026, in equal quarterly installments, and require continued service through each vesting date. Following this award, the filing shows 100,000 derivative securities held directly.
JUPITER NEUROSCIENCES, INC. reported a compensation-related stock option grant to its Chief Financial Officer, Saleem Elmasri. He received options for 525,565 shares of common stock at an exercise price of $0.2783 per share, expiring on June 2, 2036.
According to the disclosure, 325,565 options were granted as a discretionary bonus for services during fiscal 2025 and 200,000 options were granted as long-term incentive compensation under the 2025 Equity Incentive Plan. The options vest over three years starting from September 2, 2026 in equal quarterly installments, conditioned on continued employment through each vesting date.
Jupiter Neurosciences CEO and Chairman Christer Rosen received a grant of 747,783 stock options for common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036, giving him the right to buy shares at that price in the future.
According to the disclosure, the options were granted under the company’s 2025 Equity Incentive Plan as a discretionary bonus for services during fiscal 2025. They vest over three years starting on September 2, 2026, in equal quarterly installments, contingent on Rosen’s continued employment.
Jupiter Neurosciences director Nicholas H. Hemmerly received a grant of stock options covering 100,000 shares of Common Stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036. They were granted under the company’s 2025 Equity Incentive Plan and vest over three years beginning on September 2, 2026, in equal quarterly installments, subject to his continued service through each vesting date. Following this grant, Hemmerly holds options for 100,000 underlying shares directly.
JUPITER NEUROSCIENCES, INC. director Julie B. Kampf received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036.
These options were granted under the company’s 2025 Equity Incentive Plan. They vest over three years in equal quarterly installments, beginning on September 2, 2026, as long as she continues to provide service through each vesting date. Following this grant, her reported option holdings from this award total 100,000 shares.
JUPITER NEUROSCIENCES, INC. reported that President and COO Alison D. Silva received a grant of stock options covering 1,027,304 shares of common stock at an exercise price of $0.2783 per share.
According to the footnote, 427,304 of these options were granted as a discretionary bonus for services during fiscal 2025, and 600,000 options were granted as long-term incentive compensation under the company’s 2025 Equity Incentive Plan. The options vest over three years, in equal quarterly installments starting on September 2, 2026, subject to continued employment, and this grant brings Silva’s reported derivative holdings to 1,027,304 options.
Jupiter Neurosciences, Inc. reported that Chief Scientific Officer Hayward Marshall received a grant of 259,231 stock options on June 2, 2026 as a discretionary bonus for services during fiscal 2025. The options have an exercise price of $0.2783 per share and expire on June 2, 2036.
The options relate to 259,231 shares of common stock and were granted under the company’s 2025 Equity Incentive Plan. They vest over three years starting September 2, 2026, in equal quarterly installments, contingent on Mr. Marshall’s continued employment, and his total options following this grant are 259,231.
Jupiter Neurosciences director Holger Weis received a grant of stock options covering 100,000 shares of common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036. They were granted under the company’s 2025 Equity Incentive Plan and vest over three years starting on September 2, 2026, in equal quarterly installments, subject to continued service.
JUPITER NEUROSCIENCES, INC. granted Chief Administrative Officer Alexander Gustaf Erik Rosen a stock option award covering 341,843 shares of common stock. The options have an exercise price of $0.2783 per share and expire on June 2, 2036.
The grant was made as a discretionary bonus for services rendered during fiscal 2025 under the company’s 2025 Equity Incentive Plan. The options vest over three years starting September 2, 2026, in equal quarterly installments, subject to Rosen’s continued employment through each vesting date.
Jupiter Neurosciences, Inc. is issuing and selling 7,142,858 shares of its common stock in a registered direct offering at $0.28 per share, for aggregate gross proceeds of approximately $2.0 million before fees. The placement is being conducted under an effective Form S-3 registration statement declared effective April 24, 2026, and the offering is being managed by D. Boral Capital LLC as placement agent.
The company agreed to customary transaction documents including a Securities Purchase Agreement and a Placement Agency Agreement, a 7.0% cash placement fee to the placement agent, a 30-day standstill/lock-up on certain issuances and a thirty-day holder lock-up for directors, officers and >=5% holders. Legal opinion from Mintz, Levin is attached as an exhibit.